Andere Sprachen Black Diamond Therapeutics, Inc. OTC Markets

Aktien

A2PYWB

US09203E1055

BDTX

Verzögert OTC Markets Andere Börsenplätze			% 5 Tage	% 1. Jan.
- ^USD	-.--%		-.--%	-.--%

01.06.	Black Diamond Therapeutics, Inc. präsentiert vielversprechende klinische Daten zu Bdtx-1535 bei Patienten mit rezidivierendem Glioblastom auf der Jahrestagung 2024 der American Society of Clinical Oncology (Asco)	CI
16.05.	BLACK DIAMOND THERAPEUTICS, INC. : HC Wainwright behält seine Kaufempfehlung bei	ZM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	01.06.
Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting	01.06.
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	01.06.
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference	29.05.
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference	29.05.
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09.05.
Black Diamond: Q1 Earnings Snapshot	09.05.
Black Diamond Therapeutics : Reports First Quarter 2024 Financial Results and Provides Corporate Update - Form 8-K	09.05.
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24.04.
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes	11.04.
Black Diamond Therapeutics Announces Changes to Board of Directors	11.04.
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients	08.04.
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting	08.04.
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting	08.04.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	03.04.
Black Diamond: Q4 Earnings Snapshot	12.03.
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12.03.
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12.03.
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Black Diamond Therapeutics, Inc. OTC Markets

Aktien

A2PYWB

US09203E1055

BDTX

Andere Sprachen

Filter